Pharmaceutical Care for an Acute Myeloid Leukemia Patient with Agranulocytosis with Fever

doi:10.19803/j.1672-8629.2019.09.08

Abstract

Abstract: Objective To analyze the role of clinical pharmacists in pharmaceutical care of acute myeloid leukemia patients with agranulocytosis with fever. Methods One case of acute myeloid leukemia with agranulocytosis with fever after chemotherapy was discussed about its infection treatment regimen. Suggestions were made according to the symptoms and the rapeutic effects. Results The involvement of pharmacists in pharmaceutical care improved therapeutic effect and ensured medication safety. Conclusion Clinical pharmacistis, working collabortively with physicians in pharmaceutical care for special patients can maximize the treatment benefits for patients, and ensure the effectiveness and safety of drug therapy.

Key words: acute myeloid leukemia, agranulocytosis with fever, infection treatment

CLC Number:

R971

WANG Ying, YIN Peng, GUAN Liying, ZHU Kun. Pharmaceutical Care for an Acute Myeloid Leukemia Patient with Agranulocytosis with Fever[J]. Chinese Journal of Pharmacovigilance, 2019, 16(9): 561-565.

References

[1] 张程亮,张庆.1例白血病合并侵袭性肺部真菌感染患者的药学监护[J].中国药物应用与监测,2012,9(2):97-99.
[2] 中华医学会血液学分会,中国医师协会血液科医师分会.中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)[J].中华血液学杂志,2016,37(5):353-359.
[3] Averbuch D,Orasch C,Cordonnier C,et al.Europeanguidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia[J]. Haematologica,2013,98(12):1826-1835.
[4] 杜小红,张丕胜,庄贤栩,等.头孢他啶联合阿米卡星对白血病化疗后粒细胞缺乏合并感染患者血清hs-CRP、PCT、IL-6水平及预后的影响[J]. 中华全科医学,2017,15(11):1894-1896.
[5] Rhodes A,Evans LE,Alhazzani W,et al.Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Crit Care Med,2017,45(3): 486-552.
[6] Martin Greg S,Mannino David M,Eaton Stephanie, et al.The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med,2003,348(16):1546-1554.
[7] Roberts JA,Stove V,Dewaele JJ,et al.Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study[J]. Int J Antimicrob Agents,2014,43(5):423-430.
[8] Mimoz O,Rolland D,Adoun M,et al.Steady state trough serum and epithelial lining fluid concentrations of teicoplanin 12mg/kg per day in patients with ventilator-associated pneumonia[J]. Intensive Care Med,2006,32(5):775-779.
[9] 卢克鹏,宋洪涛.糖肽类抗生素在治疗MRSA感染中的PK/PD与给药方案的研究进展[J].中国医院药学杂志,2014,34(11):952-957.
[10] Toyoguchi T,Nakagawa Y.Nephrotoxicity and drug interaction of vancomycin(2)[J]. Nihon Yakurigaku Zasshi,1996,107(5):225-235.
[11] Nagahama Y,Vanbeek M J,Jdw G.Red man syndrome caused by vancomycin powder[J].Journal of Clinical Neuroscience,2018,4(4):221-225.
[12] 中华人民共和国国家卫生健康委员会.关于印发碳青霉烯类抗菌药物临床应用专家共识等3个技术文件的通知[EB/OL]. (2018-09-21)[2019-03-06].http://www.nhc.gov.cn/yzygj/s7659/201809/b44339ebef924f038003e1b7dca492f2.shtml.
[13] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J].中华内科杂志,2017,56(6):453-459.
[14] 王舒莉,崔渤莉,孟月生,等.恶性血液病患者血流感染病原菌特点及危险因素分析[J].中华医院感染学杂志,2014,24(13):3182-3184.
[15] Jeremy D,Brown,Lyn-Li,et al.Voriconazole associated torsades depointes in two adult patients with haematological malignancies[J]. Medical mycology case reports,2014,4(4):23-25.
[16] 建磊磊,冀林华,等.伏立康唑治疗恶性血液病并真菌感染临床应用Meta分析[J].实用医学杂志,2015,31(14):2368-2371.
[17] 魏艳,陈英耀,郭祖德.卡泊芬净与伏立康唑在中性粒细胞缺乏伴发热患者中初始经验性抗真菌治疗的经济学评价[J].中国药房,2017,28(14):1888-1891.
[18] 崔红霞,于苏文. 125例替加环素不良反应回顾性分析[J].中国药物警戒,2018,15(8):489-492.
[19] Hang Q,Zhou S,Zhou J.Tigecycline treatment causes a decrease in fibrinogen levels[J]. Antimicrob Agents Chemother,2015,59(3):1 650-1 655.
[20] Stevens D A.Advances in systenfic antifungal therapy[J].Clin Del Tna,2012,30:657-661.
[21] 罗洪强,傅佳萍,蒋景华.恶性血液病患者医院感染危险因素及预防控制研究[J].中华医院感染学杂志,2014,24(5):1171-1173.